Keyword: Drug and Chemical Associated Technologies Association (DCAT)


Indivior Buys US Biotech Opiant

17.11.2022 -

British drugmaker Indivior has agreed to buy Opiant, a US biotech specializing in treatments for addiction and drug overdose. Indivior will pay about $145 million upfront...

Markets & Companies

EU Energy and Supply: What Will Happen Next?

26.10.2022 -

The European Commission proposed last month an emergency intervention in Europe’s energy markets to address recent dramatic price rises as the EU faces the effects of a...

Markets & Companies

Ramping Up Biomanufacturing Capacity

20.04.2022 -

Biomanufacturing for both traditional biologics and new modalities, such as cell and gene therapies, continues to be an active area of investment for CDMOs/CMOS. Some of...

Chemistry & Life Sciences

Challenges Facing Pharmaceutical Manufacturing

23.11.2020 -

Sean Diver, president of DCAT speaks about the pharmaceutical industry’s role during the Covid-19 pandemic, trends in drug manufacturing, and key issues for the EU...


Sean Diver Elected DCAT President

06.11.2020 -

On November 1, 2020, Sean Diver took the reins as President of the Drug, Chemical & Associated Technologies Association (DCAT).

Strategy & Management

Expansions in High-Potency API Manufacturing

14.09.2020 -

DCAT Value Chain Insights rounds up recent expansion activity for highly potent drug substances and drug products.

Markets & Companies

High-level Meetings, Networking, and Education

23.12.2019 - DCAT Week, held again on March 23-26, 2020, in New York City, is a premier business development event for companies engaged in pharmaceutical development and manufacturing...

Markets & Companies

CDMO Market Forces Re-shape of M&A Activity

19.08.2019 - Mergers and acquisitions (M&A) have played a pivotal role in the evolution of the contract development and manufacturing (CDMO) industry. However, after an especially active year...